J&J's embattled Invokana gets a boost as FDA expands label
For Johnson & Johnson’s ailing diabetes drug Invokana, the expansion of its label could be the antidote that revives sales.
On Monday, the FDA expanded the drug’s label to slow the progression of diabetic nephropathy (DKD), as well as to reduce the risk of hospitalization for heart failure in patients with type II diabetes and DKD — an indication that no other type II diabetes medicine is approved for.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
